{
  "title": "RET inhibitor",
  "content-preview": "RET kinase inhibitors are a type of targeted cancer treatment that block abnormally activated RET proto-oncogene, a protein involved in cell growth. These inhibitors are used to treat cancers like non-small cell lung cancer, medullary thyroid carcinoma, and some types of colorectal and pancreatic ca",
  "url": "https://en.wikipedia.org/wiki/RET_inhibitor",
  "pageid": 65584329,
  "title-terms": {
    "ret": 1,
    "inhibitor": 1
  },
  "content-terms": {
    "ret": 26,
    "kinase": 3,
    "inhibitors": 22,
    "type": 1,
    "targeted": 1,
    "cancer": 7,
    "treatment": 2,
    "block": 1,
    "abnormally": 1,
    "activated": 1,
    "protooncogene": 1,
    "protein": 2,
    "involved": 2,
    "cell": 4,
    "growth": 2,
    "used": 2,
    "treat": 3,
    "cancers": 4,
    "like": 1,
    "nonsmall": 2,
    "lung": 4,
    "medullary": 2,
    "thyroid": 4,
    "carcinoma": 1,
    "types": 1,
    "colorectal": 1,
    "pancreatic": 1,
    "fall": 2,
    "category": 2,
    "tyrosine": 1,
    "work": 1,
    "inhibiting": 1,
    "proteins": 1,
    "abnormal": 1,
    "cells": 2,
    "existing": 1,
    "molecules": 4,
    "two": 2,
    "main": 2,
    "categories": 1,
    "older": 2,
    "multikinase": 6,
    "recent": 1,
    "selective": 9,
    "although": 2,
    "alterations": 2,
    "found": 1,
    "low": 3,
    "frequency": 1,
    "across": 2,
    "broad": 2,
    "range": 2,
    "tumors": 5,
    "three": 1,
    "indications": 1,
    "today": 1,
    "nsclc": 6,
    "harbors": 1,
    "fusions": 10,
    "12": 1,
    "cases": 3,
    "mtc": 3,
    "activating": 1,
    "mutations": 7,
    "25": 1,
    "papillary": 1,
    "ptc": 3,
    "present": 2,
    "80": 1,
    "depending": 2,
    "region": 1,
    "2020": 4,
    "48": 1,
    "fusion": 5,
    "partners": 5,
    "cataloged": 1,
    "rearrangements": 3,
    "kif5b": 3,
    "ccdc6": 1,
    "prevalent": 2,
    "least": 1,
    "10": 1,
    "different": 3,
    "variants": 1,
    "described": 1,
    "kif5bret": 3,
    "breakpoints": 1,
    "within": 1,
    "partner": 3,
    "gene": 2,
    "clinical": 8,
    "impact": 2,
    "remains": 2,
    "unclear": 1,
    "2018": 1,
    "possess": 1,
    "targets": 3,
    "along": 3,
    "included": 2,
    "cabozantinib": 3,
    "lenvatinib": 2,
    "sunitinib": 1,
    "alectinib": 1,
    "since": 2,
    "designed": 3,
    "bind": 1,
    "specifically": 1,
    "vegfr": 1,
    "cmet": 1,
    "ckit": 1,
    "among": 5,
    "vegfrrelated": 1,
    "toxicities": 2,
    "commonly": 1,
    "precluded": 1,
    "patients": 11,
    "achieving": 1,
    "therapeutic": 2,
    "doses": 2,
    "medications": 2,
    "resulting": 1,
    "incomplete": 2,
    "inhibition": 3,
    "suboptimal": 1,
    "outcomes": 1,
    "overall": 1,
    "response": 4,
    "rates": 3,
    "orr": 1,
    "16": 1,
    "28": 1,
    "progressionfree": 2,
    "survival": 1,
    "pfs": 4,
    "hovered": 2,
    "around": 4,
    "6": 2,
    "months": 3,
    "high": 5,
    "percentage": 1,
    "requiring": 1,
    "dose": 1,
    "reductions": 1,
    "discontinuing": 1,
    "73": 1,
    "resistance": 7,
    "ontarget": 2,
    "v804": 5,
    "gatekeeper": 3,
    "residue": 2,
    "well": 7,
    "offtarget": 4,
    "mechanisms": 5,
    "egfr": 3,
    "pathway": 1,
    "activation": 1,
    "mdm2": 1,
    "amplifications": 2,
    "differences": 1,
    "efficacy": 3,
    "also": 2,
    "arose": 1,
    "nonkif5b": 2,
    "typically": 1,
    "responding": 1,
    "better": 1,
    "kif5bretdriven": 1,
    "compared": 3,
    "much": 4,
    "higher": 2,
    "longer": 1,
    "survivals": 1,
    "achieved": 1,
    "alk": 1,
    "ros1": 1,
    "offered": 1,
    "limited": 2,
    "benefit": 2,
    "highlighted": 1,
    "critical": 1,
    "need": 1,
    "highly": 1,
    "2017": 1,
    "first": 3,
    "selpercatinib": 3,
    "loxo292": 1,
    "pralsetinib": 2,
    "blu667": 1,
    "started": 1,
    "phase": 3,
    "iii": 2,
    "trials": 2,
    "solid": 1,
    "potency": 1,
    "affinity": 1,
    "related": 1,
    "vegfrfamily": 1,
    "kinases": 2,
    "limit": 1,
    "overcome": 1,
    "acquired": 1,
    "previously": 1,
    "received": 1,
    "platinum": 1,
    "chemotherapies": 1,
    "orrs": 1,
    "60": 1,
    "median": 2,
    "17": 1,
    "notevaluable": 1,
    "ne": 1,
    "similar": 2,
    "promising": 1,
    "results": 3,
    "came": 1,
    "7080": 1,
    "18": 1,
    "22": 1,
    "encouraging": 1,
    "led": 1,
    "fda": 1,
    "approvals": 1,
    "retevmo\u2122": 1,
    "retdriven": 1,
    "may": 2,
    "approval": 1,
    "gavreto\u2122": 1,
    "retfusion": 1,
    "september": 1,
    "december": 1,
    "generation": 1,
    "include": 2,
    "g810": 5,
    "solventfront": 1,
    "met": 1,
    "kras": 1,
    "others": 1,
    "tp53": 1,
    "mutational": 1,
    "status": 1,
    "appears": 1,
    "prognosis": 1,
    "tp53mutated": 1,
    "showing": 2,
    "shorter": 1,
    "mostly": 1,
    "investigational": 1,
    "therapies": 1,
    "singlecompounds": 1,
    "several": 2,
    "currently": 2,
    "investigated": 3,
    "boston": 1,
    "therapeutics": 2,
    "bos172738": 1,
    "seemingly": 1,
    "falls": 1,
    "approved": 2,
    "firstgeneration": 1,
    "selectivity": 2,
    "vegfr2": 1,
    "activity": 3,
    "susceptibility": 1,
    "mutation": 4,
    "turning": 1,
    "point": 1,
    "tpx0046": 1,
    "compound": 1,
    "claimed": 1,
    "target": 1,
    "src": 1,
    "family": 1,
    "susceptible": 1,
    "compounds": 5,
    "helsinns": 1,
    "hm06": 1,
    "presented": 1,
    "data": 1,
    "october": 1,
    "2021": 4,
    "significant": 1,
    "individually": 2,
    "making": 1,
    "brainpenetrant": 1,
    "secondgeneration": 1,
    "inhibitor": 4,
    "trial": 2,
    "open": 1,
    "us": 1,
    "february": 1,
    "eli": 1,
    "lilly": 1,
    "announced": 1,
    "preclinical": 1,
    "lox18228": 1,
    "lox19260": 1,
    "nextgeneration": 1,
    "candidates": 2,
    "capable": 1,
    "tackling": 1,
    "tandem": 1,
    "g810v804": 1,
    "study": 2,
    "looked": 1,
    "lines": 3,
    "mouse": 1,
    "models": 1,
    "ccdc6ret": 1,
    "m918t": 1,
    "showed": 1,
    "strong": 1,
    "company": 2,
    "renamed": 1,
    "one": 1,
    "loxo260": 1,
    "expected": 1,
    "q1": 1,
    "2022": 1,
    "combinations": 1,
    "yet": 1,
    "evaluated": 2,
    "combination": 2,
    "therapyna\u00efve": 1,
    "still": 1,
    "arising": 1,
    "treatments": 1,
    "notably": 1,
    "5": 1,
    "egfrmutated": 1,
    "nonsmallcell": 1,
    "develop": 1,
    "mechanism": 1,
    "thirdgeneration": 1,
    "osimertinib": 2,
    "cohort": 1,
    "orchard": 1,
    "discontinued": 2,
    "rxdx105": 2,
    "developed": 2,
    "ignyta": 1,
    "vegfsparing": 1,
    "braf": 1,
    "acquisition": 1,
    "hoffmannla": 1,
    "roche": 1,
    "citing": 1,
    "poor": 1,
    "profile": 1,
    "parallel": 1,
    "boasted": 1,
    "75": 1,
    "rate": 1,
    "8": 1,
    "responses": 1,
    "0": 1,
    "20": 1,
    "represents": 1,
    "65": 1,
    "cited": 1,
    "reasons": 1,
    "difference": 1,
    "promoter": 1,
    "inducing": 1,
    "expression": 1,
    "would": 1,
    "result": 3,
    "reduced": 1,
    "diagnostics": 1,
    "order": 1,
    "identify": 1,
    "likely": 1,
    "companion": 1,
    "diagnostic": 1,
    "assays": 2,
    "regardless": 1,
    "alteration": 1,
    "tissuebased": 1,
    "ngs": 2,
    "gold": 1,
    "standard": 1,
    "specificity": 3,
    "sensitivity": 2,
    "case": 1,
    "rtpcr": 1,
    "proven": 1,
    "technique": 2,
    "miss": 1,
    "rare": 1,
    "fish": 1,
    "techniques": 1,
    "available": 1,
    "relative": 1,
    "subjectivity": 1,
    "test": 1,
    "proximity": 1,
    "common": 1,
    "make": 1,
    "difficult": 1,
    "discern": 1,
    "plasmabased": 1,
    "becoming": 1,
    "ease": 1,
    "use": 1,
    "circulating": 1,
    "tumor": 1,
    "dna": 2,
    "sample": 1,
    "depends": 1,
    "upon": 1,
    "shed": 1,
    "blood": 1,
    "means": 1,
    "positive": 1,
    "taken": 1,
    "certainty": 1,
    "negative": 1,
    "might": 1,
    "simply": 1,
    "mean": 1,
    "enough": 1,
    "material": 1,
    "collected": 1,
    "confirmed": 1,
    "another": 1,
    "rule": 1,
    "falsenegative": 1,
    "references": 1
  },
  "title-length": 2,
  "content-length": 754,
  "curious_frequency": 0,
  "uplifting_frequency": 3,
  "entertaining_frequency": 0,
  "sad_frequency": 0,
  "general_frequency": 0
}